摘要
糖尿病视网膜病变是糖尿病最常见的微血管并发症之一。目前认为炎症反应在糖尿病视网膜病变中起重要作用。非诺贝特、糖皮质激素、抗血管内皮生长因子药物和抗氧化类药物等均可通过抑制炎症发挥治疗作用。炎症调控也是新药研发的一个重要方向。本文对炎症反应在糖尿病视网膜病变中的作用及其相关靶点药物的研究进展进行综述,为治疗糖尿病视网膜病变提供新的思路。
Diabetic retinopathy(DR)is one of the common microvascular complications of diabetes mellitus.It is reported that inflammatory response plays an important role in the development of DR.Drugs like fenofibrate,glucocorticoid,anti-vascular endothelial growth factor drugs and antioxidants have been proven to play positive roles in treating DR by regulating the inflammatory response.It is also a trend to improve current therapies based on the inflammatory response.Therefore,this paper reviews the role of the inflammatory response in DR and related drugs,providing a new direction for the clinical treatment of DR.
作者
徐君
姚丹珍
夏金盈
李建辉
XU Jun;YAO Danzhen;XIA Jinying;LI Jianhui(Hua Mei Hospital,University of Chinese Academy of Sciences,Ningbo 315000,Zhejiang Province,China)
出处
《眼科新进展》
CAS
北大核心
2022年第8期664-668,672,共6页
Recent Advances in Ophthalmology
基金
浙江省医药卫生科技计划项目(编号:2021KY1012)。
关键词
糖尿病视网膜病变
糖尿病黄斑水肿
炎症反应
新兴治疗
diabetic retinopathy
diabetic macular edema
inflammatory response
emerging therapies
